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ABSTRACT
Tuberculosis (TB) is an infectious, airborne disease which primarily infects the
lungs. One-third of the world’s population is currently estimated to be infected with
Mycobacterium tuberculosis (Mtb), the causative agent for TB [1]. Current treatment for
this disease requires at least six months of taking multiple antibiotics with undesirable
side effects [2]. Difficulty in complying to this regimen as well as the prevalence of
HIV/AIDS has led to antimicrobial resistance seen in Mtb. In order to combat the MultiDrug Resistant and Extensively-Drug Resistant strains of the disease-causing bacteria,
preventative care and novel antibiotics are urgently needed [3]. The purpose for this
research is to design and synthesize novel and improved analogs as potential
antitubercular agents. One promising new target explored was the protein phosphoMurNAc-pentapeptide translocase (MraY) responsible for the biosynthesis of
peptidoglycan in the cell wall of Mtb [4]. Two narrow-spectrum analogs were designed
and synthesized with the collaboration of other lab members, and initial testing showed
that neither was active against Mtb.
While the MraY project was being pursued, other members of Roy lab were
developing regioselective synthetic methods for 4-fluoro-1,5- disubstituted-1,2,3triazoles. A paper by Patpi et al showed that 1,2,3-triazoles combined with
dibenzothiophene through a molecular hybridization approach led to the synthesis of
analogs with promising antitubercular activity. Because of the potential increased
pharmacokinetic properties fluorine can provide, the second part of this project sought to
create fluorinated versions of these analogs. To create the fluorinated analogs, an αfluoronitroalkene would be reacted with an azide to cyclize to the final product. While
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the azide was synthesized, the α-fluoronitroalkene moiety was not synthesized as a result
of time restrictions caused by the COVID-19 pandemic. After the synthesis of these
analogs is completed, they can be tested for antitubercular activity and, hopefully,
contribute to the fight to slow antimicrobial resistance.
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Chapter 1: Introduction & Background
Section 1.1 – Introduction to tuberculosis
History of tuberculosis and current epidemic
In many ways, humans are disconnected from their origins and much of their
history. Fossil records can be studied, and they show a glimpse of what ancient humans
experienced; but, with the progression of human languages, technologies, and
understanding of the world, there is very little that connects the current human experience
to the experiences of ancient humans. To find common ground, one can look at infectious
diseases—especially those which have coevolved with humans and which have yet to be
overcome—such as tuberculosis (TB) caused by the pathogen Mycobacterium
tuberculosis (Mtb).
Research suggests that the common ancestor of Mtb as it is known today may
have appeared 15,000-20,000 years ago. The origins of Mtb go back even further.
Mycobacteria likely originated 150 million years ago, and three million years ago East
African hominids may have been infected by an early progenitor of Mtb. As Mtb
evolved, so did human understanding and names of the disease it caused. From the name
“phthisis” in Ancient Greece to the names “consumption” and the “white plague”, many
names were based on the symptoms caused by Mtb. These included the general wasting
away and consumption patients faced as well as the pallor that was characteristic of the
disease. These and other names were used to refer to this disease until Johann Lukas
Schönlein gave the name “tuberculosis” in the mid-19th century in reference to the
“tubercles” or nodular lesions most commonly appearing on the lungs of those infected.
Additionally, around this time the clinical symptoms of TB were recognized and defined
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as a prolonged cough, difficulty breathing, and coughing up of mucus that contains
bacteria [6].
While in countries such as the United States this “white plague” may feel as far in
humanity’s past as the Black Plague, the reality is that an estimated one-third of the
world’s population is infected by Mtb. Of those infected, one in ten will experience the
active form of the disease, leaving the other 90% with an inactive, latent form of the
infection to be discussed in more detail shortly. While these odds may not sound terrible,
one-third of the world’s 7.8 billion people is 2.6 billion people; so, 260 million people
are estimated to have the active form of this disease, and, in fact, infection by Mtb is
currently the leading cause of death by a single infectious disease worldwide.
Second in total death toll to TB is HIV/AIDS, and research has shown a
concerning connection between HIV/AIDS and the outcome of TB infection.
Tuberculosis took the lives of 1.5 million people in 2018—of those, 251,000 were
coinfected with HIV. While incidence of TB cases in the United States has hit a record
low, the decline is marginal in other countries. Of the estimated 10 million new TB cases
in 2018, about two-thirds were in the following eight countries: India, China, Indonesia,
the Philippines, Pakistan, Nigeria, Bangladesh, and South Africa. Coinfection of HIV and
TB as well as antimicrobial resistance (AMR), to be discussed in more detail shortly,
have greatly contributed to the epidemic of TB as it currently stands [3].
Section 1.2 – Mycobacterium tuberculosis and antimicrobial resistance
Human immune response to Mtb
As previously mentioned, only 10% of those infected with Mtb will have the
active form of TB. The other 90% will be left with an inactive, latent form of the
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infection. While latent TB is not infectious and does not present problems to the host,
latent TB is another large obstacle in the way of accomplishing the World Health
Organization’s goal of ending the TB epidemic by the year 2030 [3]. By looking at the
immune response to Mtb, latent TB and the challenges it presents can be more clearly
understood. As an airborne pathogen, Mtb is spread through aerosol droplets by
coughing, sneezing, or
spitting and can live in
the air for several
hours [7]. As is seen in
Figure 1, the innate
immune response is
deployed first and
with less specificity to
Mtb compared to the
adaptive immune
response that follows.
Figure 1: The human immune response to Mtb begins after it is transmitted
through droplets, then the innate response begins before the adaptive
response contains the bacteria in granulomas [1].

While Mtb can infect
other organs of the

body, it primarily infects the lungs; so, the innate immune response brings inflammatory
cells to the lungs. Dendritic cells in the lymphatic system find and pick up Mtb and carry
it to the lymph nodes where the Mtb is presented, and the body can prepare an adaptive
immune response. After their activation and migration, antigen-specific (in this case,
Mtb-specifc) T-cells work with other leukocytes to contain the Mtb in granulomas. These
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granulomas contain macrophages which are phagocytic cells capable of absorbing the
bacteria. The macrophages work with other lymphocytes and fibroblasts which provide
structural support as they are the most common cells found in connective tissues. For
most, Mtb will remain contained in the granulomas; for a small portion of those infected,
the disease will progress to its active form releasing Mtb from the granulomas. Those on
medications for autoimmune diseases are especially at risk. While the suppression of
parts of the immune system is important for these diseases including HIV/AIDS, this also
suppresses the body’s ability to contain Mtb and can lead to activation of latent TB in
these patients [1].
Characterization of Mycobacterium tuberculosis and current therapy
On March 24, 1882 Robert Koch presented his Nobel Prize-winning work of
identifying, isolating, cultivating and reproducing TB by inoculation of laboratory
animals [6]. There are many characteristics of Mtb which distinguish it from other
bacteria and make it a difficult pathogen to kill. Most bacteria can be categorized as
either gram-positive or gram-negative. Both have an inner membrane; however, the key
difference between the two is that gram-negative bacteria have a much thinner layer of
peptidoglycan and have an additional outer membrane which prevents Gram iodine
solution from binding with its thin layer of peptidoglycan. Gram-positive bacteria have a
thick layer of peptidoglycan— a mesh-like protective layer made up of repeating units of
sugars and amino acids— which is easily accessible and dyed by Gram iodine stain. To
visualize gram-negative bacteria, a decolorizer is added which dissolves the outer
membrane of gram-negative bacteria allowing the bacteria to be dyed by a lighter
counterstain such as safranin without disturbing the dyed gram-positive cells [8].
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Mycobacteria have a unique cell wall which makes them neither gram-positive nor gramnegative.
While Mycobacteria have a peptidoglycan layer comparable to that of gramnegative bacteria, their outer cell membrane is much thicker; the outer membrane is
anchored by mycolic acids which are branched long chain fatty acids connected to a layer
of arabinogalactan which can be seen in Figure 3. The complexity of the outer membrane
and high presence of lipids relative to gram-negative bacteria prevents the outer
membrane of Mycobacteria from being dissolved by a decolorizer or being dyed by a
counterstain [9]. This difficulty in penetrating the cell for classification purposes also
presents significant challenges in the development of antitubercular drugs.
Antimicrobial Resistance and current TB treatment
In 1933, the first synthesized antibiotic, Prontosil, which contained sulfanilamide,
was used to successfully treat staphylococcal septicemia in a young, dying boy. Two
years later, researchers learned that sulfanilamide was metabolized to sulphonamide,
removed the dye from Prontosil, and thus began the sulphonamide era. This discovery
along with the discovery of Penicillin began the 20-year period of antibiotic discovery
now known as the Golden Age. With the end of the Golden Age came the beginning of a
new era of antimicrobial resistance (AMR). Antitubercular drugs have been far from an
exception to the persistence of antimicrobial resistance [10].
Streptomycin (STR) was the first antitubercular drug and, as such, set a trend for
the future of antitubercular drugs and the resistance they would confer. The potential of
STR to treat TB was discovered by Schatz in 1944, and the drug was used in humans two
years later with great efficacy. Very shortly after its introduction, resistance was found in
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more than 85% of cases making STR no longer an effective treatment. The need for
combination therapy to slow the rapid evolution of resistance became apparent shortly
after. The current treatment for TB consists of four drugs—rifampicin, isoniazid,
pyrazinamide, and ethambutol— collectively known as RIPE therapy shown in Figure 2.

Figure 2: The first-line treatment for TB consists of the four drugs rifampicin, isoniazid, pyrazinamide, and
ethambutol and is collectively known as RIPE therapy [2].

As is shown in Figure 3, the four drugs are used together because they each have
a different target in Mtb: rifampicin inhibits transcription by targeting RNA polymerase
and isoniazid and ethambutol
inhibit cell well synthesis by
inhibiting the synthesis of
mycolic acids and
lipoarabinomannan respectively
[11]. Recently, pyrazinamide has
been shown to degrade aspartate
decarboxylase PanD thus
inhibiting biosynthesis of
coenzyme A [12]. Standardly, the
four drugs are taken for 2

Figure 3: Antitubercular drugs, both first-line and second-line
have different targets. The genes responsible for each enzyme
can mutate and confer hereditary resistance [11].

6

months, followed by 4 months of rifampicin and isoniazid, the strongest of the 4 drugs.
RIPE therapy has been used for over 40 years; however, this treatment does present
problems. The drugs cause side effects and, as is common for many antibiotics, patients
often stop taking them when they start to feel better. The 6 month-long treatment using 4
different drugs requires patient adherence, and this is a factor that is difficult to control.
By not taking their antibiotic regimen all the way through, patients put themselves and
others in danger. When the correct dosage is not taken consistently, selective pressure
allows the Mtb which have mutations in the genes for the drug-targeted enzymes the
opportunity to confer resistance to the drug they are exposed to, and thus future
generations will receive this resistance. This is a large contribution to the current
epidemic of TB [11].
As may have been anticipated, the resistance seen in Mtb is complex. The first
category of resistant TB is multi-drug resistant (MDR) TB and is defined as Mtb that is
resistant to and therefore cannot be treated by the 2 stronger drugs of RIPE therapy:
rifampicin and isoniazid. To combat MDR TB, a variety of second-line therapeutics as
shown in Figure 4 are used. These drugs also have varying targets. As is shown in
Figure 3, aminoglycosides inhibit translation by targeting ribosomes, fluoroquinolones
inhibit replication by targeting DNA gyrase, para-aminosalicylic acid inhibits folate or
salicylic acid metabolism, and prothionamide functions like ethionamide inhibiting cell
wall biosynthesis by inhibiting the synthesis of mycolic acids. The next category of drugresistant TB is extensively drug-resistant (XDR) TB. XDR TB is resistant to at least one
injectable agent as well as one fluoroquinolone [11].
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Figure 4: The second-line therapy for the treatment of MDR TB consists of a combination of
injectable agents and oral agents [11]

An additional but possibly even more concerning contribution to drug resistant
TB is its connection to patients infected by HIV. As was stated previously, the
medications taken by patients with autoimmune diseases decrease the efficacy of the
human immune response to TB. To add to this problem, studies have also shown that
drug resistance is conferred in mice which are immune-deficient, and RIPE therapy
interferes with the efficacy of antiretroviral treatment of HIV [11]. These factors
contribute greatly to the large proportion of TB-related deaths in patients coinfected with
HIV and leave a great amount of space for improvement in TB treatment.
The BCG vaccine and need for new TB treatment
Currently, the only form of preventative care for TB is the Bacille CalmetteGuérin (BCG) vaccine. This vaccine was created from an isolated strain of
Mycobacterium bovis and has been used in various parts of the world since the 1920’s.
As a result of varying methodology for making the vaccine, many strains of the BCG
vaccine now exist [13]. The variable substrains used as well as differing policies per
country have left the efficacy of BCG largely unknown and controversial. The vaccine
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has proven mostly efficacious in the prevention of severe forms of TB on children such
as TB meningitis, but the same cannot be concluded for adults [14]. The lack of
preventative treatment and the persistence of resistant strains of TB have created the need
for new TB therapeutics. New antibiotics are needed to counter MDR and XDR TB by
exploiting new targets in Mtb and improving upon analogs with antitubercular activity.
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Chapter 2: Design and synthesis of analogs targeting MraY
Section 2.1 – Literature precedents and proposed project
One promising target for antibiotic design is phospho-MurNAc-pentapeptide
translocase (MraY). As was shown in Chapter 1, many current antibiotics target cell wall
biosynthesis since the cell
wall differentiates human
and bacterial cells. MraY is
the first integral membrane
protein involved in
biosynthesis of
peptidoglycan and, as such,
has great potential as a
possible target for
antitubercular drugs. Figure
5A shows how MraY
catalyzes the synthesis of
Lipid I to begin the process
of making peptidoglycan- the
Figure 5: (A) MraY catalyzes the first reaction of peptidoglycan
synthesis forming Lipid I. (B) UM5A is the natural substrate of
MraY; MD2 is a natural inhibitor [4].

cross network of repeating
sugar and amino acids. UDP-

MurNAc-pentapeptide (Figure 5B) carries the phosphor-MurNAc-pentaptide group that
is needed to form Lipid I, leaving uridine monophosphate as a byproduct after catalysis
limited by magnesium. Muraymycin D2 (MD2) seen in Figure 5B is a natural inhibitor
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of MraY. Recent cocrystal structures of MraY with UM5A and MD2 show the active site
activity involved for each, confirming the importance of the uracil moiety and 5’-aminoribosyl for inhibition of MraY [4]. While MD2 has proven its broad-spectrum
antimicrobial activity, other natural inhibitors such as capuramycin which contains a
caprolactam moiety have shown Mtb-specific inhibition [15]. Because the synthesis of
natural inhibitors is very involved, and they have shown poor pharmacokinetic properties,
there is a need for structure-based design and synthesis of narrow-spectrum antibiotics
which target MraY of Mtb.
The following molecules in Figure 6 were designed by Sudeshna Roy, PhD as
potential inhibitors of MraY. CAP6 was designed with the uracil moiety and 5’-amino-

ribosyl moieties which were essential to MD2 inhibition of MraY as well as a
caprolactam moiety which is found in the TB-specific natural inhibitor capuramycin.
Before synthesis of CAP6 and CAP7 began, computational studies were done to show the
potential binding in MraY. Because tunicamycin is a nucleoside antibiotic targeting
MraY, the model used to dock the compounds was the tunicamycin-MraY co-crystal
structure (5JNQ). These computational studies allowed for the comparison of CAP6 and
CAP7 to known inhibitors, so that the efficacy of the new analogs could be predicted as
shown in Table 1. The GlideScore gives insight into how well the molecule is expected
to bind the enzyme; this value can be used to determine the binding free energy of the
interaction. Because of this relationship, as the magnitude of a negative score increases,
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the more favorable or spontaneous the binding is expected to be. The experimental
reported activities are also given for the positive controls to give an idea of the possible
Compound

Positive
Controls

Designed
Compounds

Tunicamycin
MuraymycinD2 (MD2)
5-aminoribosyl uridine
Capuramycin
CAP6
CAP7

Experimental
reported
activity (µmol)
IC50 = 0.5-2.4
Kd = 0.014
Kd = 0.283
IC50 = 0.127
-

GlideScore
(kcal/mol)
-9.123
-8.882
-6.978
-6.946
-8.184
-8.334

Binding FreeEnergy
(kcal/mol)
-71.269
-69.373
-54.248
-67.428
-56.200
-62.209

Table 1: The GlideScores and binding free energies were calculated through docking studies so that the
binding of known inhibitors (positive controls) could be compared to the potential binding of CAP6 and
CAP7. The designed analogs have scores falling within in the range of positive controls and as such are
promising analogs.

value for CAP6 and CAP7. The studies showed that CAP6 and CAP7 had comparable
GlideScores and Binding Free-Energies as other known inhibitors. This confirmed that
CAP6 and CAP7 had great potential as antitubercular agents, so their syntheses became
the goal of this project.
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Section 2.2 – Results and discussion
CAP6 related reactions

Scheme 1: 5’-amino-ribosyl synthesis

In order to prepare the 5’-amino-ribosyl for CAP6 as shown in Scheme 1, the 2’
and 3’ alcohols on the ribose sugar needed to be protected while leaving the other two
alcohols available for the ensuing reactions. This was done by adding pentan-3-one and
sulfuric acid in DMF to make the product (a) with 60% yield. To then improve the
primary alcohol as a leaving group, a bulky tosyl group was added as tosyl chloride with
the base pyridine producing product (b) with a yield of 85%. Sodium azide was then
added to the solution of (b) in DMF to install the azide at the 5’-carbon. Because this
moiety was being synthesized to be added to the main chain of CAP6, DAST was added
to (c) in DCM to fluorinate the 1’-carbon. This produced the product (d) with a yield of
25% as a result of difficulty in purification; specifically, separation of the enantiomers
through silica gel column proved difficult.
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Scheme 2: Uracil attachment to the main chain

Scheme 2 shows the reactions used to prepare the main chain of CAP6 for the
additions of 5’-amino-ribosyl and caprolactam. To begin this synthesis, a two-step
reaction was used to install Evan’s chiral auxiliary which would provide specificity of the
enantiomer produced when caprolactam was added. The first step involved adding the
base TEA and pivaloyl chloride in THF. This was followed by the addition of the
auxiliary with LiCl and gave 93% yield. Following this reaction, BSA was added to a
solution of uracil and acetonitrile. When the solution became clear, (e) and a catalytic
amount of I2 were added and refluxed to yield 25% of the product (f).

CAP7 related reactions

Reaction 1: Uracil attachment to ethyl 5-bromopentanoate
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Reaction 2: Uracil attachment to 1,5-dibromopentane

In order to synthesize CAP7, uracil and caprolactam both needed to be added to a
five-carbon chain. The uracil moiety was attached to the main chains in Reactions 1 and
2. For both reactions, uracil was added to BSA in acetonitrile. Once the solution became
clear, a catalytic amount of TBAI and ethyl 5-dibromopentane and 1,5-dibromopentane
were added and yielded 50% of (g) and (h) respectively. In both cases, a disubstituted
product was formed leading to these yields. Reaction 1 would have been followed by a
reduction and bromination; rather than proceeding with these steps, Reaction 2 provided
a more effective option.

Reaction 3: Caprolactam synthesis

After uracil was added to the main chain for CAP7, caprolactam needed to be
synthesized. This was done by cyclizing lysine. Before using propylene glycol, ethanol
was used and produced no yield. While propylene glycol was more successful in
cyclizing lysine, the difficulty in removing the solvent prevented the purification of the
product (i) from being used. Attempts were made to distill propylene glycol out of the
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crude mixture; however, NMR showed that propylene glycol as well as lysine still
remained.
Section 2.3 – Conclusion and future work
Though CAP6 and CAP7 were not completed during this project, the reactions
completed contributed to the improvement of the synthetic routes for these analogs.
Shamba Chaterjee, PhD and Tomayo Berida of Roy Laboratory have continued this
project and found different synthetic routes for CAP6 and CAP7 and have tested these
compounds. The initial testing of these compounds showed that they were not active
against Mtb, but further testing will be done to determine if the compounds are active
against other bacteria.
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Section 2.4 – Characterization data and synthetic schemes
Synthetic scheme for CAP6
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Synthetic scheme for CAP7: Route 1

Synthetic scheme for CAP7: Route 2

18

(3aR,4R,6aR)-4-(azidomethyl)-2,2-diethyl-6-fluorotetrahydrofuro[3,4-d][1,3]dioxole
(d)

(R)-4-benzyl-3-(4-bromobutanoyl) oxazolidin-2-one (e)

19

Ethyl 5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl) pentanoate (g)

20

(S)-3-aminoazepan-2-one (i)

21

Chapter 3: Fluorinated triazoles in antitubercular analogs
Section 3.1 – Literature precedent and proposed project
Previous research has shown that carbazoles and dibenzofurans which exist in
natural antitubercular analogs play vital roles in their activity. Additionally, 1,2,3triazoles have been shown to have antitubercular activity when conjugated with
heterocyclic moieties. Based on these findings, Patpi used a molecular hybridization
approach of combining carbazole, dibenzofuran, and dibenzothiophene moieties with a
variety of substituted 1,2,3-triazoles to test their efficacy as antitubercular agents. Their
synthetic route consisted of synthesis of azides on the carbazoles, dibenzofurans, and
dibenzothiophene moieties which were then coupled with various substituted alkynes
through Huisgen cycloadditions to produce the analogs for testing against Mtb. The
assays used on strain H37Rv of Mtb showed that dibenzothiophene-containing analogs
had the lowest Minimum Inhibitory Concentration (MIC) values which are the lowest
values at which the compounds inhibited visible growth of Mtb and, therefore, are
preferable when smaller values. Patpi’s analog shown below has an MIC value of 1.89
µM which is
considerably lower
than that of
pyrazinamide
(50.08 µM) and
ethambutol (7.6
µM) but higher
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than that of isoniazid (0.37 µM). [5]
This compound provided a starting point for this project. By using a cyclization
technique developed by Roy lab, a fluorinated version of this analog could be
synthesized. Once synthesized, the effect of fluorine on the efficacy of the analog could
be determined through antimicrobial assays. Because of fluorine’s unique properties and
ability of the C-F bond to act as a bio-isostere of the C-H bond, it was hypothesized that
the addition of fluorine would increase the efficacy of the analog.

Mechanism 1 above was proposed by Roy lab for the synthesis of 4-fluoro, 1,5substituted triazoles. Trifluoroacetic acid coordinates with the nitro group to further
activate it as an electron withdrawing group, making the adjacent carbon act as a
nucleophile and the benzylic carbon act as an electrophile affording the cyclization as
shown. When TFA was not used, it was found that a mixture of 4-fluoro, 1,5-substituted
23

product and 5-fluoro, 1,4-substituted byproduct in a ratio of 5:2 was produced. Though
the aim of Roy lab was to find a method of producing one regioselective isomer, the latter
reaction which produces both isomers would be more useful for this product because the
analogs of interest which were synthesized by Patpi were 1,4-substituted-1,2,3-triazoles.
Section 3.2 – Results and Discussion

Synthetic scheme for azide synthesis

Because dibenzothiophene was commercially available and more affordable than
the acylated dibenzothiophene, it was the starting point for the synthesis of the azide (d).
Friedel-Crafts acylation was used to obtain product (a) with a 58% yield; this yield was
primarily a result of the production of the diacylated byproduct (b) which made
separation through silica gel column difficult. Sodium borohydride reduction was then
used to reduce the newly installed acetyl group to an alcohol (c) and produced practically
stoichiometric yields. From the alcohol in (c), the azide (d) was produced by adding
diphenylphosphoryl azide (DPPA) and the base 1,8-Diazabicyclo[5.4.0]undec-7-ene
(DBU) giving 68% yield of the product (d).
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Section 3.3 – Conclusion and Future Work
As a result of the COVID-19 pandemic, this project was not able to be completed.
Given more time, the fluoro-nitro compounds would have been synthesized so that the
cyclization leading to the final analog could be completed. Since the azide was already
synthesized, a variety of different fluoro-nitro compounds could be synthesized and
cyclized to form the 1,2,3-triazole. The synthesis of the fluoro-nitro compounds would
have been done by adding CBr3F, PPh3, and CH3I to react with the aldehyde seen in
scheme below. At the same time, the original non-fluorinated compounds would have
been synthesized through Huisgen cycloaddition. Once the fluorinated and nonfluorinated compounds were completed, they would have been tested on antimicrobial
assays to determine their efficacy. With the assistance of a collaborating lab, the
compounds would have been assayed against Mtb.

Synthetic scheme for fluoro-nitro synthesis

Though the pandemic of COVID-19 currently affecting the entire world is an
urgent matter and demands the cooperation of all individuals to slow its spread, the same
is true of TB. Diseases are forever evolving, and while research now moves faster than
ever towards new/repurposed drugs and vaccines to face them, TB has been the exception
for far too long. Though the lab is not currently accessible, this project will be continued
by gathering information for reviews to aid other researchers as well as by spreading
awareness of this disease.
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Section 3.4 – Characterization data (H1 NMR)
1-(dibenzo[b,d]thiophen-2-yl)ethan-1-one (a)

1-(dibenzo[b,d]thiophen-2-yl)ethan-1-ol (c)
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2-(1-azidoethyl)dibenzo[b,d]thiophene (d)
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Section 4.2 – Synthetic procedures for Chapter 2
CAP6 experimental procedures
(3aR,6R,6aR)-2,2-diethyl-6-(hydroxymethyl) tetrahydrofuro[3,4-d][1,3]dioxol-4-ol
(a)
Dry DMF (15 mL) was added to (3R,4S,5R)-5(hydroxymethyl)tetrahydrofuran-2,3,4-triol (1.0 g, 1 Eq, 6.7 mmol),
then treated with pentan-3-one (29 g, 35 mL, 50 Eq, 0.33 mol)
and sulfuric acid (0.65 g, 1 Eq, 6.7 mmol) in a round-bottom flask. The mixture was
stirred at room temperature for 45 hours and yielded 850 mg (58% yield) of a colorless
syrup.
(3aR,4R,6aR)-2,2-diethyl-6-hydroxytetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl 4methylbenzenesulfonate (b)

At 0°C, to a solution of protected D-ribose (1.1 g, 5.0 mmol) in pyridine
(15 mL) was added recrystallized tosyl chloride (1.4 g, 7.6 mmol). The
mixture was stirred at rt for 17 h. After completion of the reaction, the
reaction was quenched with water and EtOAc was added. The resulting
solution was transferred into a separatory funnel and washed with a 1 M
HCl aqueous solution. The organic layer was washed with brine and water,
dried (Na2SO4), filtrated and concentrated in vacuo giving 85% yield of the
crude tosylate (b) as a translucent bright orange oil. This residue was used for the
following azidation reaction.

29

(3aR,6R,6aR)-6-(azidomethyl)-2,2-diethyltetrahydrofuro[3,4-d][1,3]dioxol-4-ol (c)
Sodium azide (0.65 g, 10 mmol) was added to the protected ribose (1.6
g, 4.3 mmol) and DMF (15mL) was added to the solution in a roundbottom flask. The mixture stirred at 50°C for 18h and yielded 0.54 g
(52% yield) of (c). 1H NMR (400 MHz, Chloroform-d) δ 5.52 (d, J = 5.2 Hz, 1H), 4.74 –
4.67 (m, 2H), 4.47 – 4.35 (m, 1H), 3.63 (dd, J = 12.6, 7.0 Hz, 1H), 3.45 (dd, J = 12.6, 5.6
Hz, 1H), 3.10 (d, J = 5.2 Hz, 1H), 1.83 – 1.69 (m, 2H), 1.69 – 1.56 (m, 3H), 0.95 (dt, J =
14.7, 7.4 Hz, 6H).

(3aR,4R,6aR)-4-(azidomethyl)-2,2-diethyl-6-fluorotetrahydrofuro[3,4-d][1,3]dioxole
(d)

A solution of (c) was treated with DAST at -40°C for 30 minutes. The
reaction was quenched by addition of aqueous NaHCO3 after the TLC
showed there was no remaining starting material. Then, the organic phase
was dissolved in diethyl ether, washed with H2O and saturated aqueous
NaCl, dried (Na2SO4), filtered, and concentrated in vacuo. A column was run from 040% EA-Hex. The crude product was a slightly yellow liquid. The four spots were not
completely separated by the column leading to the 25% yield of (d). 1HNMR (400 MHz,
Chloroform-d) d 5.80 (d, J = 61.3 Hz, 1H), 4.82 (t, J = 5.9 Hz, 1H), 4.67 (dd, J = 6.0, 1.0
Hz, 1H), 4.48 (dddd, J = 7.6, 6.5, 3.5, 0.9 Hz, 1H), 3.50 (dd, J = 12.9, 7.7 Hz, 1H), 3.25
(d, J = 6.6 Hz, 1H), 1.69 (q, J = 7.4 Hz, 2H), 1.59 (q, J = 7.5 Hz, 2H), 0.89 (td, J = 7.5,
5.3 Hz, 6H).
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(R)-4-benzyl-3-(4-bromobutanoyl) oxazolidin-2-one (e)
A stirred solution of 5-bromopentanoic acid (500 mg, 1 Eq, 2.76
mmol) in dry THF (5 mL) at 0 °C was treated with triethylamine
(699 mg, 0.96 mL, 2.5 Eq, 6.90 mmol) and pivaloyl chloride (366
mg, 0.37 mL, 1.1 Eq, 3.04 mmol). The viscous suspension was stirred for 1 h. Then,
lithium chloride (129 mg, 1.1 Eq, 3.04 mmol) and (R)-4-benzyl-2-oxazolidinone
(245 mg, 1.38 mmol, 1.00 eq.) were added. The suspension was stirred at the same
temperature for 0.5 h and then warmed to room temperature and stirred for another 3 h.
Next, water (5 mL) was added and the solution was concentrated under reduced pressure.
The aqueous phase was extracted three times with EtOAc (25 mL per extraction). The
combined organic phases were dried (Na2SO4), the volatiles were evaporated under
reduced pressure and the remaining oil was filtered through silica gel. The experiment
yielded 840 mg (93.2% yield) of (e). 1HNMR (500 MHz, Chloroform-d) d 7.37 – 7.25
(m, 3H), 7.24 – 7.19 (m, 2H), 4.68 (ddt, J = 10.5, 7.2, 3.2 Hz, 1H), 4.25 – 4.16 (m, 2H),
3.45 (t, J = 6.6 Hz, 2H), 3.30 (dd, J = 13.4, 3.4 Hz, 1H), 2.98 (qt, J = 17.2, 7.2 Hz, 2H),
2.78 (dd, J = 13.3, 9.6 Hz, 1H), 2.03 – 1.79 (m, 4H).

(R)-1-(5-(4-benzyl-2-oxooxazolidin-3-yl)-5-oxopentyl) pyrimidine-2,4(1H,3H)-dione
(f)
To a suspension of Uracil (100 mg) in dry acetonitrile
(32 mL) was added trimethylsilyl N-(trimethylsilyl)
acetimidate (448 mg, 541 µL, 2.5 Eq, 2.20 mmol) under
argon. After the reaction mixture became a clear solution (half an hour), (e) (300 mg, 1
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Eq, 882 µmol) and a catalytic amount of iodine (11.2 mg, 0.05 Eq, 44.1 µmol) were
added. The reaction solution was heated at reflux for 72 h to yield a brown colored
solution. Monitoring the reaction by TLC showed unreacted uracil and bromooxazolidinone. After cooling to room temperature, the mixture was quenched with water,
diluted with ethyl acetate. Precipitation was observed. The organic layer was removed,
and the aqueous layer was washed with EtOAc. The combined organic layer was washed
with water, brine and dried over Na2SO4 and evaporated to dryness. The residue was
purified by flash chromatography (40-100% EtOAC in hexane as eluent) to give (f) as
a white foamy compound with 25% yield.
CAP7 experimental procedures
Ethyl 5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl) pentanoate (g)

To a suspension of Uracil (281 mg) in dry
acetonitrile (32 mL) was added trimethylsilyl N(trimethylsilyl) acetimidate (2.27 g, 2.74 mL, 2.5 Eq,
11.2 mmol) under argon. After the reaction mixture became a clear solution (half an
hour), ethyl 5-bromopentanoate (2.80 g, 2.12 mL, 3 Eq, 13.4 mmol) and a catalytic
amount of TBAI (165 mg, 0.1 Eq, 446 µmol) were added. The reaction solution was
heated at reflux for 3 days. The reaction was quenched by adding water dropwise and was
worked up in ethyl acetate. The reaction yielded 51% yield of the product (g). 1H NMR
(500 MHz, Chloroform-d) δ 8.37 (s, 1H), 7.15 (d, J = 7.9 Hz, 1H), 5.69 (dd, J = 7.9, 2.3
Hz, 1H), 4.13 (q, J = 7.1 Hz, 2H), 3.74 (t, J = 7.1 Hz, 2H), 2.36 (t, J = 7.1 Hz, 2H), 1.80 –
1.70 (m, 2H), 1.70 – 1.63 (m, 2H), 1.25 (t, J = 7.1 Hz, 3H).
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1-(5-bromopentyl) pyrimidine-2,4(1H,3H)-dione (h)

To a suspension of Uracil (1 g) in dry acetonitrile (15 mL)
was added trimethylsilyl N-(trimethylsilyl) acetimidate (2 g,
1 Eq, 9 mmol) under argon. After the reaction mixture
became a clear solution (half an hour), 1,5-dibromopentane (5 g, 3 mL, 2 Eq, 0.02 mol)
and a catalytic amount of tetrabutylammonium iodide (3 g, 1 Eq, 9 mmol) were added.
The reaction solution was heated at reflux for 3 days. The reaction was run in a vial and
the white inner circle of the lid could not withstand the heat of the reaction and fell into
the mixture. The lid was replaced after the first day of running and TLC showing the
reaction was not complete. The white substance kept the stir bar from being able to stir.
After 3 days, and the addition of a second equivalent of 1,5-dibromopentane (5 g, 3 mL, 2
Eq, 0.02 mol), the TLC still showed starting material, but the reaction was stopped. The
reaction was quenched by adding water drop-wise and was worked up in ethyl acetate
and yielded 50% (g).

(S)-3-aminoazepan-2-one (i)

(S)-2,6-diammoniohexanoate (500 mg, 1 Eq, 3.40 mmol) was neutralized
by sodium hydroxide (136 mg, 1 Eq, 3.40 mmol), then about 25 mL of
propylene glycol was added to the round bottom flask. A dean stark trap was used to
collect any water produced by the reaction. The mixture was heated to 200°C and
allowed to reflux for 2 hours. The reaction mixture was distilled to remove propylene
glycol which led to charring of the product before all of the propylene glycol could be
removed. Because the propylene glycol could not be removed, the yield was not
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determined. A crude NMR confirmed the formation of caprolactam. 1H NMR (500 MHz,
Methanol-d4) δ 4.21 – 4.16 (m, 1H), 3.28 – 3.21 (m, 2H), 2.13 – 2.06 (m, 1H), 2.00 –
1.94 (m, 1H), 1.93 – 1.85 (m, 1H), 1.83 – 1.68 (m, 2H), 1.47 – 1.38 (m, 1H).

Chapter 3 Reactions
1-(dibenzo[b,d]thiophen-2-yl)ethan-1-one (a)

Aluminum chloride (0.80 g, 1.1 Eq, 6.0 mmol) was first measured
out in a vial and flushed with argon. To this vial was added DCM (5
mL), then acetyl chloride (0.85 g, 0.77 mL, 2 Eq, 11 mmol). In a
separate vial, dibenzo[b,d]thiophene (1.0 g, 1 Eq, 5.4 mmol) was measured out and DCM
(10 mL) was added. The activated solution of dibenzothiophene in DCM was then added
dropwise to the solution of activated acetyl chloride. The reaction stirred at 40°C for 6
hours and yielded (a) and the diacylated byproduct (b). A column was run from 0-100%
DCM in Hexane. Starting material was recovered at around 30% DCM- Hexane. The
diacylated product (b) came out first at around 40% DCM-Hexane. The column was run
at 40% DCM-Hexane for at least 300mL. The product also began to come out at about
40% DCM-Hexane. After just the product was leaving the column, the solvent system
was gradually increased to 100% DCM to finish pushing the product through. The
product was concentrated and gave about a 58% yield of (a). Yield for the diacylated
product (b) was not determined as a result of the COVID-19 pandemic preventing access
to the lab. 1H NMR (400 MHz, Chloroform-d) δ 8.79 (d, J = 1.7 Hz, 1H), 8.32 – 8.25 (m,
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1H), 8.09 (dd, J = 8.4, 1.8 Hz, 1H), 7.96 (d, J = 8.4 Hz, 1H), 7.93 – 7.88 (m, 1H), 2.77 (s,
3H).

1-(dibenzo[b,d]thiophen-2-yl)ethan-1-ol (c)
Sodium borohydride (179 mg, 1.5 Eq, 4.74 mmol) was added to the
solution of (a) in 1:1 DCM: methanol (8mL total) in a tall vial at
0°C, then stirred at RT for an hour. The crude reaction mixture was
evaporated under vacuum before water and DCM were added, and the organic layer was
separated, washed with H2O, dried over anhydrous Na2SO4, and filtered. The organic
layer was concentrated yielding the product (c) with 99% yield. 1H NMR (400 MHz,
Chloroform-d) δ 8.24 – 8.14 (m, 1H), 7.92 – 7.77 (m, 1H), 7.55 – 7.43 (m, 2H), 5.13 (q, J
= 6.4 Hz, 1H), 1.63 (d, J = 6.4 Hz, 2H).

2-(1-azidoethyl) dibenzo[b,d]thiophene (d)

A mixture of (c) (330 mg, 1 Eq, 1.45 mmol) and diphenyl
phosphorazidate (597 mg, 467 µL, 1.5 Eq, 2.17 mmol) were
suspended in dry THF in a tall vial. At 0 °C, DBU (330 mg, 327
µL, 1.5 Eq, 2.17 mmol) was added, and the mixture was warmed to room temperature
and stirred overnight (12 h). After consumption of starting material was confirmed by
TLC, DCM and water were added to the crude mixture. The organic layer was separated
and concentrated. A column was run from 0-100% to collect the product (d) with a 58%
yield. 1H NMR (400 MHz, Chloroform-d) δ 8.24 – 8.18 (m, 1H), 8.14 (d, J = 1.8 Hz,
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1H), 7.93 – 7.83 (m, 2H), 7.54 – 7.48 (m, 2H), 7.46 (dd, J = 8.3, 1.8 Hz, 1H), 4.85 (q, J =
6.8 Hz, 1H), 1.67 (d, J = 6.8 Hz, 3H).
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